Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 8 | 2023 | 687 | 0.860 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 676 | 0.730 |
Why?
|
| Kidney Neoplasms | 5 | 2023 | 160 | 0.720 |
Why?
|
| Urethral Stricture | 4 | 2023 | 69 | 0.650 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2023 | 103 | 0.620 |
Why?
|
| Lichen Sclerosus et Atrophicus | 4 | 2023 | 20 | 0.580 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 168 | 0.360 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 349 | 0.330 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 770 | 0.260 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2021 | 52 | 0.200 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 510 | 0.200 |
Why?
|
| Urethra | 2 | 2021 | 75 | 0.200 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 105 | 0.180 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 5 | 0.180 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 8 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 259 | 0.170 |
Why?
|
| Virus Internalization | 1 | 2021 | 88 | 0.160 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 114 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 174 | 0.160 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 61 | 0.160 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 98 | 0.150 |
Why?
|
| Ureteral Neoplasms | 1 | 2018 | 8 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 262 | 0.150 |
Why?
|
| Gene Expression | 1 | 2021 | 840 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 43 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1647 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 165 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 508 | 0.130 |
Why?
|
| Prognosis | 4 | 2022 | 1749 | 0.130 |
Why?
|
| Dasatinib | 1 | 2016 | 5 | 0.130 |
Why?
|
| Humans | 19 | 2024 | 63511 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 31 | 0.120 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2016 | 26 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2016 | 64 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2022 | 279 | 0.120 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 92 | 0.120 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 322 | 0.120 |
Why?
|
| Middle Aged | 9 | 2024 | 17644 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 198 | 0.110 |
Why?
|
| Aged | 8 | 2024 | 14472 | 0.110 |
Why?
|
| Male | 11 | 2024 | 29927 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 697 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6673 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2023 | 988 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 346 | 0.080 |
Why?
|
| Female | 9 | 2024 | 32912 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2023 | 525 | 0.070 |
Why?
|
| Nephrectomy | 2 | 2020 | 91 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 422 | 0.070 |
Why?
|
| Mutation | 1 | 2016 | 2614 | 0.070 |
Why?
|
| Biopsy | 2 | 2019 | 444 | 0.060 |
Why?
|
| Kidney | 2 | 2020 | 447 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2017 | 265 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 1471 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 5474 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 2462 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 1173 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 2082 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1409 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2574 | 0.050 |
Why?
|
| Administration, Intravesical | 1 | 2023 | 13 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 16837 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 129 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 45 | 0.050 |
Why?
|
| Bronchi | 1 | 2022 | 81 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2021 | 130 | 0.050 |
Why?
|
| Cathepsin L | 1 | 2021 | 22 | 0.040 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2021 | 9 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 27 | 0.040 |
Why?
|
| Cell Movement | 1 | 2023 | 454 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 69 | 0.040 |
Why?
|
| Respiratory System | 1 | 2021 | 46 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 173 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 84 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2021 | 195 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2023 | 256 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 584 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 37 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 71 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 218 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2020 | 297 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5699 | 0.040 |
Why?
|
| Transfection | 1 | 2021 | 694 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 293 | 0.040 |
Why?
|
| Weight Loss | 1 | 2020 | 274 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 644 | 0.030 |
Why?
|
| Smoking | 1 | 2022 | 866 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 873 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 897 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1094 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 65 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 921 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1008 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 320 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 10846 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 851 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 54 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 956 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 190 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1147 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1147 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 3301 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 20666 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2187 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7852 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4700 | 0.020 |
Why?
|